Edition:
United States

Celldex Therapeutics Inc (CLDX.OQ)

CLDX.OQ on NASDAQ Stock Exchange Global Select Market

2.79USD
23 Oct 2017
Change (% chg)

-- (--)
Prev Close
$2.79
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
303,531
52-wk High
$5.01
52-wk Low
$2.20

Select another date:

Wed, Aug 23 2017

BRIEF-Celldex announces completion of enrollment in phase 2b study of Glembatumumab Vedotin in triple negative breast cancer

* Celldex announces completion of enrollment in phase 2b study of Glembatumumab Vedotin in triple negative breast cancer

BRIEF-Celldex Therapeutics Q2 loss per share $0.23

* Celldex Therapeutics - Q2 revenue $3.8 million versus $1.4 million

BRIEF-Celldex Therapeutics Q2 loss per share $0.23

* Q2 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-Celldex Therapeutics promotes Sam Martin as CFO

* Celldex Therapeutics announces additions to the board of directors and senior management team

BRIEF-Celldex presents data from phase 2 study of glembatumumab vedotin

* Celldex presents promising overall survival data from phase 2 study of single-agent glembatumumab vedotin in patients with checkpoint-refractory metastatic melanoma

BRIEF-Celldex reports Q1 loss per share $0.28

* Q1 earnings per share view $-0.29 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

Select another date: